Sahajanand Medical Technologies (SMT) IPO 2026: Date, Price Band and Details

Dates, price band, lot size, financials and full details of the Sahajanand Medical Technologies Limited IPO, sourced from the company's Red Herring Prospectus (RHP).
SMT IPO at a glance
| Detail | Value |
| IPO Dates | 15 to 19 Oct 2026 |
| Price Band | ₹327 to ₹344 |
| Issue Size | About ₹475.48 crore |
| Lot Size | 43 shares |
| Minimum Investment | ₹14,792 |
| Listing Date | 23 Oct 2026 |
Sahajanand Medical Technologies Limited (SMT) is bringing a Book Built Mainboard IPO worth about ₹475.48 crore at the upper price band. The issue is entirely an Offer for Sale (OFS), with no fresh issue, so the company receives no proceeds. The IPO is open from 15 October to 19 October 2026 and is proposed to list on the BSE and the NSE.
SMT IPO Details
| Particulars | Details |
| IPO Type | Book Built Mainboard IPO |
| Total Issue Size | About ₹475.48 crore (up to 1,38,22,116 shares at the upper price band) |
| Fresh Issue | None. The issue is entirely an Offer for Sale. |
| Offer for Sale (OFS) | Up to 1,38,22,116 shares by promoter, promoter group and investor selling shareholders |
| Price Band | ₹327 to ₹344 per share |
| Face Value | ₹1 per share |
| Lot Size | 43 shares |
| Minimum Retail Investment | ₹14,792 (1 lot, at upper price band) |
| Employee Reservation | Up to 2,50,000 shares reserved for eligible employees |
| Listing On | BSE and NSE |
| Lead Managers | Motilal Oswal Investment Advisors, Avendus Capital, HSBC Securities and Capital Markets (India), Nuvama Wealth Management |
| Registrar | MUFG Intime India Private Limited |
SMT IPO Timelines
| Event | Date |
| IPO Opens | 15 October 2026 |
| IPO Closes | 19 October 2026 |
| Allotment | 21 October 2026 |
| Refund Initiation | 22 October 2026 |
| Credit of Shares to Demat | 22 October 2026 |
| Listing Date | 23 October 2026 |
Dates are tentative and may change.
SMT IPO GMP
GMP stands for Grey Market Premium. It is the extra amount some traders are willing to pay for IPO shares in an informal market before listing, on top of the issue price. This market runs outside the stock exchanges, so the figure is unregulated, unverified, and can move sharply within a single day. A high GMP does not confirm a listing gain, and a low one does not rule it out, because it tracks short-term sentiment rather than the worth of the business. A steadier read on the IPO comes from the company's financials, how it uses its money, its valuation, and the risk factors set out in the Red Herring Prospectus (RHP).
About Sahajanand Medical Technologies Limited
Originally incorporated as Sahajanand Medical Technologies Private Limited in October 2001 and converted into a public limited company in 2021, SMT was founded by Mr. Dhirajlal Kotadia. It is a research-driven medical devices company that designs and manufactures technologically advanced cardiovascular implants, classified as Class III (and Class C/D) devices. Its registered office is in Surat, Gujarat, and its corporate office is in Mumbai.
Its portfolio spans Vascular Intervention products, such as coronary drug-eluting stents (DES) and balloons, and Structural Heart products, such as TAVI systems (transcatheter aortic valve implantation) and occluders, along with its own renal stents and other products. Vascular Intervention devices made up about 61% of revenue from operations in FY 2026. According to the F&S Report cited in the RHP, SMT has a leading DES market share in India of about 25% by sales volume in FY 2026, and it is among the top five DES companies by sales volume in Germany, Spain, Poland and Brazil.
SMT marketed its products in 77 countries (including India) in FY 2026, through a mix of direct, hybrid and distributor-led models. It operates three manufacturing facilities, including a unit in the Surat Special Economic Zone, and two research and development centres (one in India and one in Thailand). The company's promoters are Bhargav Dhirajlal Kotadia, Dhirajlal Vallabhbhai Kotadia, Priyanka Dhirajlal Cohen and Shree Hari Trust.
What are the Key Strengths of SMT (as stated in the RHP)
- Technologically advanced products in segments with high barriers to entry.
- Proven research and development capabilities across product categories and platform technologies.
- Leadership in India and key international markets across products.
- Deep global sales and marketing presence leading to fast growth in diversified international markets.
- Diversified, integrated, and efficient manufacturing facilities accredited by regulatory authorities.
- Proven mergers and acquisitions and strategic collaborations playbook.
- Experienced leadership team backed by reputed institutional investors.
What the Money Will Be Used For
This IPO is entirely an Offer for Sale (OFS). This means the existing shareholders listed below are selling part of their shares to the public. Because there is no fresh issue, the company itself does not receive any money from this IPO. All the proceeds, after expenses, go to the selling shareholders.
| Selling Shareholder | Shares Offered (up to) |
| Shree Hari Trust (Promoter) | 27,00,000 |
| Dhirajkumar Savjibhai Vasoya (Promoter Group) | 20,00,000 |
| Samara Capital Markets Holding Limited (Investor) | 64,79,063 |
| NHPEA Sparkle Holding B.V. (Investor) | 13,35,178 |
| Kotak Opportunities Fund (Pre-IPO Investor) | 13,07,875 |
The company's stated aims are to achieve the listing benefits of trading its shares on the stock exchanges and to carry out the Offer for Sale.
What are the Company Financials of SMT
Restated consolidated figures, in ₹ crore.
| Particulars | FY 2026 | FY 2025 | FY 2024 | 2-Yr CAGR |
| Revenue from Operations | 1,210.50 | 1,024.88 | 901.60 | 15.87% |
| Total Income | 1,218.73 | 1,035.96 | 908.59 | 15.82% |
| Profit After Tax (PAT) | 69.08 | 25.15 | (7.35) | N/A |
| EBITDA | 170.66 | 128.02 | 110.05 | 24.53% |
| Net Worth | 695.46 | 565.73 | 540.09 | 13.48% |
2-Yr CAGR is calculated from FY 2024 to FY 2026. Revenue grew steadily each year. The company reported a loss at the PAT level in FY 2024 and returned to profit in FY 2025 and FY 2026, so a 2-year PAT growth rate cannot be calculated. EBITDA and EBITDA margin (14.10% in FY 2026) are the figures the RHP discloses. Net Worth is the equity attributable to the owners of the company.
Who Can Apply
The offer, less the employee reservation, is split across investor categories as follows:
| Category | Share of the Net Offer |
| Qualified Institutional Buyers (QIB) | Not more than 50% |
| Non-Institutional Investors (NII) | Not less than 15% |
| Retail Individual Investors (RII) | Not less than 35% |
In addition, up to 2,50,000 shares are reserved for eligible employees under the Employee Reservation Portion.
How to Apply for the SMT IPO
You can apply online through your broker app or through your bank's net banking using the Application Supported by Blocked Amount (ASBA) facility.
- Log in to your broker app or your bank's net banking.
- Open the IPO section and select Sahajanand Medical Technologies IPO.
- Enter the number of lots and your bid price, or select the cut-off price.
- Enter your Unified Payments Interface (UPI) ID, or confirm your bank account for the ASBA route.
- Submit the application form.
- Approve the mandate request in your UPI app to block the funds until allotment.
How to Check Allotment Status
The basis of allotment is expected to be finalised on 21 October 2026. Once it is out, you can check your allotment status in three ways. You will need your PAN, application number, or DP/Client ID.
- On the registrar's website, MUFG Intime India, at the public issues page.
- On the BSE or NSE website under the IPO allotment section.
- Inside your broker app, under orders or IPO history.
Key Risk Factors
The RHP lists several risk factors. A few of the key ones are summarised below. Please read the full RHP for the complete list.
- The business is subject to extensive medical device regulation across jurisdictions (such as the EU Medical Device Regulation and Indian rules), and any adverse regulatory action, or a failure to obtain, renew or maintain the many product certifications and licences it needs, could affect operations.
- The company and certain of its subsidiaries have incurred losses in the past, including a loss at the PAT level in FY 2024.
- A majority of revenue comes from Vascular Intervention devices (about 61% in FY 2026), so a slowdown in that segment would hit the business hard.
- A large share of revenue is earned outside India, which exposes the company to foreign exchange movements and overseas regulatory and pricing risks.
- Operations are working-capital intensive, and any inability to maintain an optimal level of working capital could affect the business.
- The company is exposed to product liability claims and product recalls, given the safety-critical, implantable nature of its devices.
- It faces intense competition from large global medical device companies and must keep pace with rapid technological change.
- Future growth depends on research and development and on new product development and approvals, which are uncertain and can be delayed.
- The company has undertaken, and may continue to pursue, acquisitions and third-party collaborations, which carry integration and goodwill risks.
- There are outstanding legal and tax proceedings against the company, its subsidiaries and directors, and it has been unable to locate certain of its historical corporate records.
- Some manufacturing facilities operate within a Special Economic Zone (SEZ), which carries specific restrictions, and the company has in the past regularised and compounded certain non-compliances with exchange control regulations.
Frequently Asked Questions (FAQs)
1. When does the SMT IPO open and close?
The IPO opens on 15 October 2026 and closes on 19 October 2026.
2. What is the price band of the IPO?
The price band is ₹327 to ₹344 per share.
3. What is the lot size?
One lot is 43 shares. Applications are made in multiples of 43 shares.
4. What is the minimum investment for retail investors?
The minimum investment is ₹14,792 at the upper price band (1 lot of 43 shares).
5. Is this IPO a fresh issue?
No. It is entirely an Offer for Sale by existing shareholders, so the company receives no proceeds from the issue.
6. When is the allotment date?
The allotment is expected to be finalised on 21 October 2026, with shares credited to demat accounts by 22 October 2026.
7. When is the listing date?
The shares are proposed to be listed on the BSE and the NSE on 23 October 2026 (tentative).
8. What does Sahajanand Medical Technologies do?
It is a medical devices company that designs and manufactures cardiovascular implants, including drug-eluting stents, balloons, TAVI systems and occluders, selling across 77 countries with a leading DES market share in India.
9. What is the GMP of the SMT IPO?
GMP, or Grey Market Premium, is an informal pre-listing price that sits outside the stock exchanges and is neither regulated nor verified. It shifts with day-to-day sentiment and does not confirm how the shares will list. A more reliable picture comes from the company's financials, valuation, and the risks in the RHP.
Read the full Red Herring Prospectus (RHP): View the official RHP filed with SEBI and the exchanges.
Disclaimer: This page is for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any securities. All figures are sourced from the company's Red Herring Prospectus and public filings and may change. Investments in securities are subject to market risks. Please read all offer documents carefully and consult a registered financial advisor before making any investment decision.
